184 related articles for article (PubMed ID: 23756575)
1. Denileukin diftitox plus total skin electron beam radiation in patients with treatment-refractory cutaneous T-cell Lymphoma (mycosis fungoides): report of four cases.
Buder K; Müller PA; Beckmann G; Ugurel S; Bröcker EB; Becker JC
Acta Derm Venereol; 2014 Jan; 94(1):94-6. PubMed ID: 23756575
[No Abstract] [Full Text] [Related]
2. Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides.
Assaf C
Dermatol Clin; 2008 Jan; 26 Suppl 1():21-2. PubMed ID: 18405182
[No Abstract] [Full Text] [Related]
3. Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox.
Wobser M; Göppner D; Lang SC; Beckmann G; Flentje M; Ugurel S; Bröcker EB; Becker JC
Arch Dermatol; 2010 Jul; 146(7):805-6. PubMed ID: 20644054
[No Abstract] [Full Text] [Related]
4. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
Talpur R; Duvic M
Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
[TBL] [Abstract][Full Text] [Related]
5. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?
Bunn PA
Arch Dermatol; 1995 May; 131(5):603-5. PubMed ID: 7537952
[No Abstract] [Full Text] [Related]
6. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
Chin KM; Foss FM
Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
[TBL] [Abstract][Full Text] [Related]
7. Denileukin diftitox.
Saxon M
Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
[TBL] [Abstract][Full Text] [Related]
8. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
[TBL] [Abstract][Full Text] [Related]
9. A complete and durable response to denileukin diftitox in a patient with mycosis fungoides.
Carretero-Margolis CD; Fivenson DP
J Am Acad Dermatol; 2003 Feb; 48(2):275-6. PubMed ID: 12582402
[TBL] [Abstract][Full Text] [Related]
10. Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox.
Dao H; Barr PM; Honda K
J Am Acad Dermatol; 2011 Jun; 64(6):e123-5. PubMed ID: 21571160
[No Abstract] [Full Text] [Related]
11. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
[TBL] [Abstract][Full Text] [Related]
12. Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox.
Kazin R; Bujanauskas P; Vonderheid EC
J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S31-2. PubMed ID: 18191695
[No Abstract] [Full Text] [Related]
13. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
Dang NH; Pro B; Hagemeister FB; Samaniego F; Jones D; Samuels BI; Rodriguez MA; Goy A; Romaguera JE; McLaughlin P; Tong AT; Turturro F; Walker PL; Fayad L
Br J Haematol; 2007 Feb; 136(3):439-47. PubMed ID: 17233846
[TBL] [Abstract][Full Text] [Related]
14. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
Talpur R; Duvic M
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
[TBL] [Abstract][Full Text] [Related]
16. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides.
Ghori F; Polder KD; Pinter-Brown LC; Hoff AO; Gagel RF; Sherman SI; Duvic M
J Clin Endocrinol Metab; 2006 Jun; 91(6):2205-8. PubMed ID: 16595600
[TBL] [Abstract][Full Text] [Related]
17. Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
Wong BY; Gregory SA; Dang NH
Cancer Invest; 2007 Sep; 25(6):495-501. PubMed ID: 17882663
[TBL] [Abstract][Full Text] [Related]
18. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK).
Talpur R; Apisarnthanarax N; Ward S; Duvic M
Leuk Lymphoma; 2002 Jan; 43(1):121-6. PubMed ID: 11908715
[TBL] [Abstract][Full Text] [Related]
19. Denileukin diftitox.
Figgitt DP; Lamb HM; Goa KL
Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
[TBL] [Abstract][Full Text] [Related]
20. Denileukin diftitox: a concise clinical review.
Eklund JW; Kuzel TM
Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
